Lonza , the world’s largest contract drug manufacturer, on Wednesday set 2026 targets for its contract development and manufacturing organization (CDMO) business, expecting slower sales growth of 11% to 12% at constant exchange rates and for its core profit margin to expand to above 32% of sales.
The Swiss company added it expected sales growth to be higher in the first half of 2026 than in the second half.
Sign up here.
In 2025, the CDMO business, which was split off from the capsule and health ingredients (CHI) business which Lonza is plann… [906 chars]
Source: Reuters | Published: 2026-01-28T05:49:03Z
Credit: Reuters
